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Abstract:  
 Background: Perampanel (PMP), a noncompetitive α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) glutamate receptor antagonist, is a novel antiepileptic drug 
(AED) licensed for the adjunctive treatment of focal and generalized epilepsy. There is 
limited information on PMP’s pharmacokinetics and drug interaction characteristics with 
concomitant AEDs. We have investigated the effects of PMP dose, age, gender and co-
prescribed AEDs on serum PMP concentrations. 
Methods: We used the database of a therapeutic drug monitoring unit at a tertiary epilepsy 
referral centre to identify patients who had PMP as part of their treatment and extracted 
clinical information from their medical notes.  Sera PMP concentrations had being 
determined by using liquid chromatography/mass spectroscopy.   
Results: In total, 160 sera from 107 patients (66 females) aged 18-70 years and weighing 40-
125 kg were identified. They were prescribed a median PMP dose of 6 mg/day (range 2-12 
mg/day) and were co-prescribed a variety of AEDs including enzyme-inducing 
(carbamazepine and oxcarbazepine) and enzyme-inhibiting (valproic acid) AEDs. A linear 
relationship was observed between PMP dose and serum concentrations (r2 = 0.714, 
p<0.0005). Gender and age were found not to influence PMP serum concentration. Enzyme-
inducing AEDs dose-dependently decreased PMP concentrations, with carbamazepine and 
oxcarbazepine decreasing mean values by 69% and 37% respectively. In contrast, whilst 
topiramate and phenytoin also decreased mean PMP concentrations by 18% and 13% 
respectively, these changes did not achieve statistical significance.  
Conclusions: PMP exhibits a linear dose-concentration relationship, with serum PMP 
concentrations being age and gender independent. Carbamazepine and oxcarbazepine can 
significantly decrease PMP concentrations, probably via an induction of CYP3A4-mediated 
metabolism.  
 
Running title: Perampanel serum concentrations in epilepsy 
 
 
Key words: new antiepileptic drug, pharmacokinetic drug-drug interactions, carbamazepine, 
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Introduction 
 
Perampanel (PMP) is a novel antiepileptic drug (AED) recently licensed for the adjunctive 
treatment of patients with focal and generalized epilepsies aged ≥12 years of age.1 PMP is a 
selective non-competitive AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-
receptor antagonist; a unique mechanism of action for an AED.2,3 
 
PMP has some pharmacokinetics properties which could be advantageous in clinical use. 
These include fast absorption (Tmax 0.5-2.5 hours) the extent of which is not affected by 
food co-ingestion, a bioavailability of 100%, and linear pharmacokinetics. Its volume of 
distribution is 1.1 L/kg and protein binding is 95%. PMP serum steady-state concentrations 
are achieved in 10-19 days. The serum elimination half-life PMP is ~48 hours in healthy 
volunteers and ~25 hours in both healthy volunteers and patients with epilepsy co-prescribed 
carbamazepine. PMP is extensively metabolised, primarily via cytochrome P450 (CYP) 3A4 
but CYP3A5 may also contribute, to produce several pharmacologically inactive 
metabolites.4 Clearance is reportedly unaffected by age and race5, although it was found to be 
17% slower in women compared to men.6  
 
At clinically relevant concentrations, PMP in vitro is neither a potent inducer nor inhibitor of 
CYPs or uridine 5’-diphospho-glucuronosyltransferase (UGT) isoenzymes and thus it is not 
anticipated to cause pharmacokinetic interactions. However, since PMP is metabolised via 
CYP3A4, an isoenzyme responsible for the metabolisms of many drugs including various 
AEDs, would suggest that it may be susceptible to pharmacokinetic interactions. Indeed  in 
the pooled population pharmacokinetic analysis7 of three Phase III randomized clinical trial 
studies in 969 patients with focal seizures,8-10 patients co-prescribed carbamazepine (n=379), 
oxcarbazepine (n=201), phenytoin (n=91) or topiramate (n=226) all experienced an increase 
in PMP clearance. Thus, PMP area under the serum concentration-time curves (AUC) 
decreased by 67%, 50%, 50% and 20% respectively for carbamazepine, oxcarbazepine, 
phenytoin and topiramate. For carbamazepine, a study in 20 healthy male volunteers has 
shown that carbamazepine administration increased the apparent oral clearance of PMP three-
fold and the mean AUC values were decreased by 26%.4 
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We used serum PMP concentration data collected for therapeutic drug monitoring (TDM) in 
an adult population of patients with epilepsy to assess the effect of daily PMP dose, gender, 
age and concomitant AED therapy on steady-state serum PMP concentrations. TDM 
databases are particularly useful in providing robust confirmation of pharmacokinetic 
interactions noted by other investigative methodologies and indeed can serve to highlight as 
yet unknown pharmacokinetic interactions.11     
 
Materials and Methods 
Study Population 
Data were retrospectively collected from  109 adults attending the specialist epilepsy clinics 
of the National Hospital for Neurology and Neurosurgery (Queen’s Square and Chalfont 
sites), during the period January 2013 and December 2014 who had serum samples collected  
for AED concentration  determination, as part of their of their routine clinical management. 
Specific ethical approval was not needed because it entailed retrospective data generated as 
part of their routine clinical management. 
 
PMP Analysis  
PMP concentration analysis was undertaken by high-performance liquid 
chromatography/mass spectroscopy (LC/MS) using a fully validated methodology in routine 
use within the TDM Unit at the Chalfont Centre for Epilepsy. Validation was based on the 
most recent versions of the guidelines on bionalytical method validation of the European 
Medicines Agency and the US Food and Drug Administration.12,13  Briefly, an Agilent 1200 
series automated LC with an Agilent 6400 series triple quad MS (Agilent Technologies, 
Stockport, Cheshire, UK) and a HiQ sil C18 column were used. Sera (24 µL) were extracted 
with 500 µL acetonitrile and prepared for LC/MS analysis by use of a Gilson Quad-Z215 
liquid handler (Gilson Instrumentation Services, Luton, Bedfordshire, UK). Calibration curve 
linearity was observed over the concentration range of 2-800 µg/L. The lower limit of 
quantification for PMP was 2.0 µg/L and the lowest limit of detection was 1.0 µg/L. The 
inter-assay and intra-assay coefficient of variation was 3.7-4.6% and 1.8-2.2% respectively. 
The measurement uncertainty for PMP was 4.2%.    
 
Blood samples 
In total, 160 samples were collected, with some patients being sampled on multiple occasions 
as their PMP dose was up-titrated. As PMP is only approved as adjunctive therapy, all but 6 
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patients (who were on PMP monotherapy) were treated with PMP in combination with other 
AEDs (Table 1). 
 
Data collection was achieved by first reviewing the TDM Unit’s archived request for analysis 
forms and reports and secondly by searching through each individual’s medical records. 
Information gathered included age, gender, body weight, PMP dosage and concurrent blood 
concentration, as well as concomitant AEDs, their doses and their concurrent blood 
concentrations. For AED comedication, although some blood samples were collected at 
trough (i.e. just before the next dose), most were collected up to 3 hours post AED ingestion 
and reflects every day AED TDM clinical practice. For PMP, these sampling times 
represented approximately 12 hours post ingestion because patients typically ingest their 
PMP medication at bed time the evening before. Only patients whose PMP blood 
concentrations were at steady-state were included in this study. Steady state was considered 
to occur when the same PMP dose was prescribed for 10-19 days (i.e. equivalent to PMP 5 
half-life values). These values are based on a calculated effective half-life of PMP of 48 
hours and simulation of a pooled Phase I model of a sample size of 1,000 volunteers 
receiving 4 mg/day PMP whereby 90% of subjects achieved 90% steady-state by day 19. 4 
 
PMP blood samples were divided into sub-groups according to AED comedication namely: A 
= PMP monotherapy and samples from those neither on enzyme-inducing AEDs or enzyme-
inhibiting AEDs, Group B = co-prescription of enzyme-inducing AEDs, Group C = co-
prescription of enzyme-inhibiting AEDs and Group D = co-prescription of both an enzyme-
inducing and an enzyme-inhibiting AED (Table 1).     
 
Statistical Analysis 
Statistical analysis was undertaken using SPSS 21.0 for Macintosh. Correlations were 
determined by use of the Pearson’s correlation statistic and variances between means were 
determined by use of the Levene statistic followed by the Dunnett or Bonferoni post hoc 
testing for multiple comparisons depending on variance significance. Results were considered 
statistically significant when p-values were below the 0.05 level. 
 
Results 
In total, 160 samples of serum PMP concentrations were collected from 107 individuals (66 
females) (Table 1). This resulted in 68 male and 92 female serum samples. All had a 
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diagnosis of focal epilepsy. Mean age was 42 years (range, 18-70 years), and mean body 
weight was 77 kg (range, 40-125 kg). Body weight measurements were not available for all 
subjects. The mean PMP concentration for the 160 samples was 353 µg/L (95% CI: 306-403), 
and ranged 2-1621 µg/L. 
 
For the purposes of data analysis, sera from patients co-prescribed non-enzyme-inducing 
AEDs, with no influence on CYP3A4/5, as well as samples from those prescribed PMP as  
monotherapy, were considered to be controls (n=50). Five individuals were on PMP 
monotherapy (median dose, 6 mg/day) with a mean (± sd) serum PMP concentration of 379 ± 
223 µg/L. 
 
PMP concentrations in the control group (Group A) exhibited dose linearity as determined by 
Pearson correlation analysis (0.621 p<0.0003; Figure 1). Linear analysis, however, did not 
identify any gender or age effect on PMP serum concentrations (p=0.421 and p=0.393 
respectively). 
 
Table 2 summarizes the mean PMP serum concentrations and the PMP serum concentration 
versus dose ratios (CDRs) in the different groups. Compared with sera from those not 
prescribed enzyme-inducing or enzyme-inhibiting AEDs (Group A), mean PMP serum 
concentrations in sera from patients co-prescribed enzyme-inducing AEDs (Group B) were 
significantly lower (500 ± 326 versus 217 ± 20 µg/L; p < 00005). The CDR values followed 
the same pattern.  
 
Mean PMP serum concentrations in sera from individuals  co-prescribed valproic acid, a 
known inhibitor of CYP enzymes (Group C), were not significantly different compared to 
sera from those  not prescribed enzyme-inducing or enzyme-inhibiting AEDs (Group A). 
Consequently, comparing mean PMP serum values in Group B with that of  patients co-
prescribed valproic acid, Group B had significantly lower mean serum PMP concentrations 
(p<0.05).  The presence of both an enzyme-inducing AED and that of valproic acid resulted 
in lower mean serum PMP concentrations although this did not achieve statistical 
significance.  
 
In order to investigate the specific effects of individual AEDs on PMP serum concentrations, 
samples were sub-grouped according to which single enzyme-inducing AED was co-
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prescribed. If patients were co-prescribed more than one enzyme-inducing AED, they were 
excluded from the analysis. As a result of these criteria, no samples were identified so as to 
investigate the effect of either phenobarbital or primidone; both AEDs are known to be potent 
enzyme inducers. For carbamazepine 28 samples were identified, for oxcarbazepine 31, 
phenytoin 8 and topiramate 3. Compared to control samples (50), the mean PMP 
concentration in those co-prescribed carbamazepine was 69% lower (mean PMP 
concentration 134.9 µg/L; range 105.6-159.5 µg/L; 95% CI -77% to -58%). Those co-
prescribed oxcarbazepine, the mean serum PMP concentration was 37% lower (mean PMP 
concentration 262.2 µg/L; range 222.7-301.7 µg/L; 95% CI: -54% to -21%). Topiramate and 
phenytoin, mean serum PMP concentrations were not significantly lower than that of control 
group samples, however values were lower. Topiramate was associated with an 18% decrease 
in the mean PMP concentration (95% CI: -62% to 25%) whilst phenytoin was associated with 
a 13% decrease in PMP concentrations (95% CI: -57% to 31%). The data for carbamazepine 
and oxcarbazepine are illustrated in Figure 2 which show a dose-dependent effect with 
correlation coefficients of -0.642 (p<0.005) and -0.528 (p<0.005) respectively.  
 
Figure 3 shows the relationship between PMP dose and serum PMP concentrations in 3 
individuals who had been sampled on 3 separate occasions for TDM and were co-prescribed 
different concomitant AEDs. For each, PMP exhibited linear pharmacokinetics with PMP 
serum concentrations increasing with increasing PMP dose. The PMP serum concentrations 
achieved in subject 3, who was not co-prescribed enzyme-inducing AEDs, were substantially 
higher than for subject 1 who was co-prescribed the enzyme-inducing AED carbamazepine (a 
potent inducer) and subject 2 who was co-prescribed 2 enzyme-inducing AEDs, 
oxcarbazepine and phenytoin (moderate inducers).   
 
Lastly, as animal data suggested that lamotrigine and levetiracetam can decrease PMP serum 
concentrations by 38% and 17% respectively14 and as these AEDs are often prescribed, we 
sought to evaluate these potential interactions in our cohort. We identified 13 patients who 
were co-prescribed lamotrigine and 20 co-prescribed levetiracetam. No other AED was co-
prescribed to these. Compared to mean serum PMP concentrations achieved in controls, 
neither lamotrigine nor levetiracetam had a significant effect on mean serum PMP 
concentrations (mean PMP concentration: 358.7 µg/L and 342.1 µg/L, range 54.0-945.0 µg/L 
and 2.0 -1143. µg/L, respectively). 
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Discussion 
PMP dose both in terms of mg/day and mg/kg/day are linearly related to serum PMP 
concentrations (r2 =0.481, p=0.0004 for mg/day vs r2 =0.714, p=0.0001 for mg/kg/day) and 
these data are in agreement with those reported by Gidal et al.7 Dose linearity is an important 
characteristic as this allows straightforward dosing strategies and it aids the prediction of the 
effect of dose titration and adjustment which may improve treatment outcome. 
 
There is a significant relationship between increases in PMP serum concentrations and 
reduction in seizure frequency.7 Increases in serum PMP concentrations may also be 
associated with increases in PMP-related adverse effects.7 Also, efficacy increases with 
increasing PMP serum concentrations regardless of whether or not enzyme-inducing AEDs 
are co-prescribed.15 This characteristic supports the strategy of dosing PMP to clinical effect 
guided by TDM. The current putative  therapeutic range for PMP is 180-980 µg/L.4 With 
regards to PMP TDM, the fact that PMP has a long half-life (48 hours), which consequently 
only necessitates once a day dosing, means that diurnal oscillations of  serum PMP 
concentrations is minimal and therefore samples can be collected at any time during a dosing 
interval. Furthermore, the long-half life of PMP means that missing a dose should have a 
minimal effect on serum PMP concentrations; although consequent to the extensive 
metabolism of PMP in patients co-prescribed enzyme-inducing AEDs, serum PMP 
concentration may decline to a clinically significant extent 7 and in this setting the missed 
dose should be ingested upon identification of a missed dose.        
 
An important challenge in the management of patients with epilepsy is firstly the recognition 
of drug-drug interactions and secondly undertaking the appropriate adjustment of doses so as 
to circumvent the often undesirable outcome.16,17 At present, PMP is given as add-on therapy 
and therefore it is important to consider potential drug interactions. Indeed, like many AEDs, 
PMP appears to be susceptible to such interactions and this was first highlighted in the pooled 
population pharmacokinetic analysis of 969 patients with partial epilepsy who participated in 
three Phase III randomized clinical trial studies. Mean PMP AUC values in patients co-
prescribed carbamazepine decreased by 67%, whilst those co-prescribed oxcarbazepine 
decreased by 50%. In those co-prescribed phenytoin and topiramate mean PMP AUC values 
decreased by 50% and 20% respectively.4 Our present data, derived from a TDM database, 
corroborate the published population data in terms of magnitude of the different individual 
AEDs and their relative effects. Thus, carbamazepine has the strongest inducing effect 
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whereby its co-prescribing resulted in a mean 69% lower PMP serum concentration (n=23). 
Oxcarbazepine co-prescribing (n=25) resulted in a mean 37% lower PMP concentration. With 
regards to topiramate (n=3) and phenytoin (n=8), mean serum PMP concentrations were 18% 
and 13% lower compared to that of control group samples; but these data did not achieve 
statistical significance probably because the sample size was small. For carbamazepine and 
oxcarbazepine, their effect on decreasing PMP serum concentration was linearly related to 
their respective doses (r2 = -0.642, p<0.005; r2 =-0.531, p<0.005 respectively). These drug 
interactions appear to be unidirectional because in vitro PMP does not have a significant 
effect on isoenzymes responsible for the metabolism of carbamazepine, oxcarbazepine, 
phenytoin or topiramate4.  
 
Valproic acid, at clinically relevant concentrations, is a potent competitive inhibitor in vitro 
of CYP2C9 with only a slight effect on CYP2C19 and CYP3A4 activities.18 In addition, 
clinical data indicate that it is a potent inhibitor of UGT1A4 activity.19 Consequently, 
valproic acid inhibits the metabolism of numerous AEDs including phenytoin, phenobarbital 
and lamotrigine and raises their serum concentrations. Since VPA has only a slight inhibitory 
effect on CYP3A4, the principal isoenzyme responsible for the metabolism of PMP, it is not 
surprising that serum PMP concentrations were unaffected by valproic acid co-administration 
(Table 2).     
 
Recently published animal (rat) data report that lamotrigine and levetiracetam can decrease 
PMP serum concentrations by 38% and 17% respectively.14 However, it should be 
remembered that rats may metabolize AEDs via different isoenzymes, they exhibit faster 
metabolism and also higher drug doses are often required in rats so as to achieve serum AED 
concentrations typically achieved clinically.20  In the present study, 13 and 20 patients were 
identified respectively who were co-prescribed lamotrigine and levetiracetam only, and not 
on any concomitant enzyme-inducing AED. Compared to mean serum PMP concentrations 
achieved in those not prescribed enzyme-inducing AEDs, neither lamotrigine nor 
levetiracetam had a significant effect on mean serum PMP concentrations. Our data are not 
surprising bearing in mind that neither lamotrigine or levetiracetam are known to affect 
CYP3A4 isoenzyme activity and corroborate the lack of effect of these two AEDs (n=357; 
n=330 respectively) reported in the population pharmacokinetic evaluation of the three Phase 
III randomized clinical trial studies.4     
 
AC
CE
PT
ED
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
Page 10 of 16 
 
Analysis of PMP oral clearance values in the 1,478 subjects that participated in the three 
phase III studies by gender, showed that females (n=759) exhibited a mean 17% lower 
clearance than that of males (n=719).6 Our data, based on steady-state PMP serum 
concentrations did not show any gender differences (mean ± sd): 490±344 µg/L (n=75; all 
patients); 501±344 µg/L (n=28; males); 484±347 µg/L (n=46; females) for Groups A+C 
combined. Other AEDs which exhibit gender differences with regards to their 
pharmacokinetics include lacosamide,21 lamotrigine,22 pregabalin,23 clobazam,24 valproic 
acid, 25 carbamazepine,26 ethosuximide27 and rufinamide.28 Other AEDs have not been 
systematically studied in this regards. 
 
It is particularly interesting to examine the cases in which multiple PMP doses and blood 
samples were available for analysis (Figure 3).  All 3 exhibited PMP linear pharmacokinetics 
despite their different co-prescriptions. What is particularly noteworthy is that the slope of the 
curve of subject 3, who was not co-prescribed an enzyme-inducing AED, was particularly 
steep compared to subjects 1 and 2 who were co-prescribed enzyme-inducing AEDs. 
Interestingly, it would appear that co-prescribing two relative weak enzyme-inducing AEDs 
(oxcarbazepine and phenytoin) has approximated the same effect on PMP serum 
concentration as occurs with a strong enzyme-inducing AED (carbamazepine).   
 
Conclusion 
Our analyses of a PMP TDM database shows that PMP exhibits dose linearity, that 
concentrations were age and gender independent but were significantly affected by co-
prescribed AEDs. Enzyme-inducing AEDs such as carbamazepine and oxcarbazepine 
resulted in lower mean PMP serum concentrations compared with those not co-prescribed 
such AEDs. Lower serum PMP concentrations were also observed in those co-prescribed 
phenytoin and topiramate, but possibly because of small serum number, these effects did not 
achieve statistical significance.  These data concur with earlier published population 
pharmacokinetic data that PMP clearance can be enhanced by enzyme-inducing AEDs. 
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Table 1: Sera and clinical characteristics. 
 
Number of subjects  107 
Number of sera  160 
Gender (male/female) 41/66 
Age (years) 
       Mean: 
       Range: 
 
41 
18-70 
Seizure type 
       Partial seizures: 
       Partial seizures with secondary 
       Generalization: 
 
83 
24 
Body weight (kg) 
       Mean: 
       Range: 
       Number of subjects with documented  
       body weight: 
 
77 
40-125 
 
92 
PMP dose (mg/day) 
       Median:  
       Range: 
 
6 
2-12 
PMP dose (mg/kg/day) 
       Median:  
       Range: 
 
0.08 
0.019-0.331 
Number of concomitant AEDs (samples) 
Group A: PMP monotherapy: 
Non-enzyme-inducing/non- 
                 enzyme-inhibiting AEDs in  
                 combination (CLB, CZP, ESM, 
                 GBP, LEV, LTG, LCM, PGB, 
                  RTG, VGB, ZNS): 
 
Group B: Enzyme-inducing AEDs: 
              CBZ: 
              OXC: 
               PB: 
               PHT: 
               TPM: 
               PRM: 
   
Group C: Enzyme-inhibiting AEDs: 
                VPA: 
Group D: Enzyme-inducing and enzyme- 
inhibiting AEDs: 
 
 
5 
 
 
 
 
45 
 
74 
31 
35 
7 
22 
3 
5 
 
 
25 
 
11 
  
 
CBZ, carbamazepine; CLB, clobazam; CZP, clonazepam; ESM, ethosuximide; GBP, 
gabapentin; LEV, levetiracetam; LTG, lamotrigine; LCM, lacosamide; OXC, oxcarbazepine; 
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PMP, perampanel; PB, phenobarbital; PHT, phenytoin; PGB, pregabalin; PRM, primidone; 
RTG, retigabine; TPM, topiramate; VPA, valproic acid; VGB, vigabatrin; ZNS zonisamide. 
 
 
 
 
 
 
 
 
Table 2: Mean serum perampanel (PMP) concentrations and serum PMP concentration versus 
dose ratios (CDRs) in the different groups. 
 
Group n-value Mean PMP 
concentration 
(µg/L) 
Group 
comparison 
Mean PMP 
concentration 
difference 
(µg/L) 
p-value 
A 50 500 ± 326    
B 74 217± 201 A vs B -283* P<00005 
C 25 468± 384 A vs C -32 P=1.00 
D 11 340± 167 A vs D -160 P=0.166 
 160  B vs C   251* P<0.028 
      
Group n-value Mean PMP 
CDR 
Group 
comparison 
Mean PMP 
CDR  
p-value 
A 29 6016± 3613    
B 38 2369± 2128 A vs B -3648* P=0002 
C 19 7116± 3741 A vs C   1099 P=0.891 
D 6 3407± 1569 A vs D -2610 P=0.063 
Total n 91  B vs C   4747* P=002 
 
* = statistically significant difference 
 
A = control group (patients on PMP monotherapy + those not prescribed enzyme-inducing 
or enzyme-inhibiting antiepileptic drugs [AEDs]. 
B = patients co-prescribed enzyme-inducing AEDs 
C = patients co-prescribed enzyme-inhibiting AEDs 
D = patients co-prescribed both enzyme-inducing and enzyme-inhibiting AEDs AC
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ED
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Figure Legends 
 
Figure 1: Correlation between PMP dose (mg/kg) and PMP serum concentrations (µg/L) in 
Group A (PMP control group, n=29) and Group B (co-prescribed enzyme-inducing AEDs, 
n=38). (Group A; r2 = 0.621; p=0.0003; Group B; r2 = 0.325, p=0.046) 
 
Figure 2: The relationship between PMP dose (mg/day) and PMP serum concentrations 
(µg/L) in the PMP control group (n=50), patients co-prescribed carbamazepine (n=31, mean 
dose: 1186 mg, range: 400-2200) and patients co-prescribed oxcarbazepine (OXC; n=35, 
mean dose: 1398 mg, range: 450-3100 mg).  Co-prescription with carbamazepine (CBZ) 
resulted in lower PMP concentration values (mean: 135 µg/L; range 10-428 µg/L) compared 
to co-prescription with OXC (mean: 262 µg/L; range: 2-912 µg/L). 
 
Figure 3: Relationship between perampanel (PMP) dose (mg/day) and PMP serum 
concentrations (µg/L) in 3 individuals co-prescribed different antiepileptic drugs (AEDs). For 
each PMP exhibited linear pharmacokinetics with PMP serum concentrations increasing with 
PMP dose (r2 values were 0.983, 0.784 and 0.971 respectively). The slope of the curves was 
dependent on concomitant AEDs – Subject  1 (a female, aged 42, weight 73 kg) was co-
prescribed carbamazepine (a potent enzyme inducer of CYP3A4) and clobazam; Subject 2: (a 
male, aged 36, weight 82kg) was co-prescribed  phenytoin (an enzyme inducer of CYP3A4), 
oxcarbazepine (an enzyme inducer of CYP3A4) and levetiracetam; Subject 3 (a female, aged 
40, weight 70 kg) co-prescribed valproic acid and clobazam (neither AED is known to have 
an effect on CYP3A4 isoenzymes). 
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